Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of February 2019. The report serves to notify shareholders of a rescheduled Extraordinary General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding corporate governance and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of the Extraordinary General Meeting of Shareholders. Originally scheduled for February 22, 2019, the meeting has been postponed to March 17, 2019, at noon Israel time. The agenda, record date, and meeting location remain unchanged.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document focuses on the appointment of an independent registered public accounting firm for the fiscal year ending December 31, 2018, and authorizing the Board to determine their compensation. Proxies signed for the original date remain valid for the rescheduled meeting.
Key Facts for Investor Verification
- Meeting Date: The Extraordinary General Meeting is now scheduled for March 17, 2019.
- Record Date: Shareholders of record as of the close of trading on February 5, 2019, are entitled to vote.
- Proxy Validity: Existing proxies signed for the original February 22 date do not need to be resubmitted.
- Meeting Agenda: Appointment of the independent registered public accounting firm and authorization of auditor compensation for the 2018 fiscal year.
- Signatory: The report was signed by Dr. Dalia Megiddo, Interim Chief Executive Officer.